Leerink Partnrs Issues Optimistic Forecast for TNDM Earnings

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) – Stock analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for Tandem Diabetes Care in a research report issued on Thursday, February 27th. Leerink Partnrs analyst M. Kratky now forecasts that the medical device company will post earnings of ($0.56) per share for the quarter, up from their prior estimate of ($0.66). The consensus estimate for Tandem Diabetes Care’s current full-year earnings is ($1.68) per share. Leerink Partnrs also issued estimates for Tandem Diabetes Care’s Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($1.07) EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.08) EPS and FY2028 earnings at $0.31 EPS.

A number of other brokerages also recently commented on TNDM. Barclays lowered their price objective on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Canaccord Genuity Group reissued a “buy” rating and issued a $63.00 target price on shares of Tandem Diabetes Care in a research report on Wednesday, February 26th. The Goldman Sachs Group decreased their target price on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating for the company in a research report on Monday. Wells Fargo & Company reissued an “equal weight” rating and issued a $22.00 target price (down from $38.00) on shares of Tandem Diabetes Care in a research report on Monday. Finally, Morgan Stanley raised shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 target price for the company in a research report on Monday, December 2nd. Seven investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Tandem Diabetes Care presently has an average rating of “Moderate Buy” and a consensus price target of $46.81.

Tandem Diabetes Care Stock Performance

Shares of TNDM opened at $19.49 on Monday. The company’s 50 day moving average price is $34.28 and its 200 day moving average price is $35.98. Tandem Diabetes Care has a 52 week low of $18.77 and a 52 week high of $53.69. The company has a market capitalization of $1.30 billion, a PE ratio of -10.10 and a beta of 1.32. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90.

Hedge Funds Weigh In On Tandem Diabetes Care

Several large investors have recently bought and sold shares of TNDM. Hood River Capital Management LLC acquired a new position in Tandem Diabetes Care during the 4th quarter valued at $46,035,000. Jacobs Levy Equity Management Inc. raised its stake in Tandem Diabetes Care by 189.0% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,661,013 shares of the medical device company’s stock valued at $59,830,000 after purchasing an additional 1,086,337 shares during the last quarter. Brown Advisory Inc. acquired a new position in Tandem Diabetes Care during the 4th quarter valued at $32,889,000. Park West Asset Management LLC raised its stake in Tandem Diabetes Care by 49.5% during the 4th quarter. Park West Asset Management LLC now owns 1,600,000 shares of the medical device company’s stock valued at $57,632,000 after purchasing an additional 530,000 shares during the last quarter. Finally, Baillie Gifford & Co. raised its stake in Tandem Diabetes Care by 235.7% during the 4th quarter. Baillie Gifford & Co. now owns 746,109 shares of the medical device company’s stock valued at $26,875,000 after purchasing an additional 523,843 shares during the last quarter.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.